The mysterious coronavirus outbreak in the Chinese city Wuhan, now termed as Covid-19, and its fast spread to many other countries, endangers thousands of lives. infecting nearly 93,000 people and killing more than 3,000. What makes the coronavirus scary enough to cause a worldwide run on face masks and lead countries to lock down whole megacities and ban travelers isn’t that it’s super deadly.At this palce, you can get the details about everything you need to know about Coronavirus
The pandemic has catalysed the development of novel coronavirus vaccines across the biotech industry, both by pharmaceutical companies and research organizations such as the National Institutes of Health (NIH), US.
The first Covid-19 vaccine in China is expected to be ready for clinical trials by the end of April, according to Xu Nanping, China’s vice-minister of science and technology. Inovio Pharmaceuticals plans to begin clinical trials on a coronavirus vaccine in April this year.
Here is a list of the major coronavirus drugs that pharmaceutical companies across the world are developing that have the potential to become major coronavirus vaccines or antivirals for treating the contagious coronavirus infection.
Listed below are the coronavirus vaccines in various stages of development, across the world.
Altimmune’s intranasal coronavirus vaccine
An intranasal Covid-19 vaccine is being developed by US-based clinical-stage biopharmaceutical company, Altimmune.
Design and synthesis of the single-dose vaccine has been completed, while animal testing will follow.
The coronavirus vaccine is being developed based on a vaccine technology platform that is similar to NasoVAX, an influenza vaccine developed by Altimmune.
INO-4800 by Inovio Pharmaceuticals and Beijing Advaccine Biotechnology
Inovio Pharmaceuticals has collaborated with Beijing Advaccine Biotechnology Company to advance the development of the former’s vaccine, INO-4800, as a novel coronavirus vaccine. The company has started pre-clinical testing for clinical product manufacturing.
The vaccine development is supported by a $9m grant from the Coalition for Epidemic Preparedness Innovations (CEPI).
Inovio announced an accelerated timeline for the development of the vaccine on 03 March. Preclinical trials are ongoing and the design for human clinical trials have been completed. The company has also prepared 3,000 doses for human clinical trials planned to be conducted across the US, China, and South Korea. Plans for large-scale manufacturing have also been developed.
Human clinical trials in 30 healthy volunteers are expected to commence in April 2020 in the US, followed by China, and South Korea. A phase one clinical trial is planned to be conducted in parallel in China, by Beijing Advaccine. Results from the clinical trials are expected to be available in September 2020.
Inovio aims to produce one million doses of the vaccine by the end of 2020 to perform additional clinical trials or emergency use.
APN01 by University of British Columbia and APEIRON Biologics
A drug candidate developed by APEIRON Biologics named APN01 is being tested in China in a phase one pilot trial as a treatment for Covid-19. APN01 is based on research conducted by a professor at the University of British Columbia for treating SARS. The research revealed that the ACE2 protein was the main receptor for the SARS virus.
mRNA-1273 vaccine by Moderna and Vaccine Research Center
Moderna and the Vaccine Research Center, a unit of the National Institute of Allergy and Infectious Diseases (NIAID), have collaborated to develop a vaccine for coronavirus. The vaccine targets the Spike (S) protein of the coronavirus.
The first vials of the vaccine have been manufactured at Moderna’s Massachusetts manufacturing plant and shipped to NIAID for phase one clinical trial, which is scheduled to start in April.
Avian Coronavirus Infectious Bronchitis Virus (IBV) vaccine by MIGAL Research Institute
The MIGAL Research Institute in Israel announced that an Infectious Bronchitis Virus (IBV) vaccine developed to treat avian coronavirus has been modified to treat Covid-19. The vaccine has demonstrated efficacy in pre-clinical trials conducted by the Volcani Institute.